![肿瘤药物治疗方案及综合评价](https://wfqqreader-1252317822.image.myqcloud.com/cover/13/43604013/b_43604013.jpg)
晚期乳腺癌维持化疗方案
方案 GT方案
将转移性乳腺癌患者,6程GT方案肿瘤控制良好的患者,随机分配至继续GT方案维持治疗组或停药观察组。
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T142_297_1495_2009_1788_92631.jpg?sign=1738892202-7vJLak3nkTcRdIvpEBFRt0YjN2dScE0q-0-b6205b913931972b924488696e846581)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T142_290_1887_2033_2846_148420.jpg?sign=1738892202-55UHPprEuOddiKntYeEemUYpysVIvoyx-0-4dbd4366dfda6ef6191ecdb0a52cd6d8)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T143_221_371_1956_1590_148422.jpg?sign=1738892202-QQVjlQeNKWD117pfGI6R1WPWxQuUBEkD-0-7be7b4be0c6148ae06296a3991461f8f)
点评
转移性乳腺癌患者,GT方案控制良好的情况下,继续延长化疗可进一步延长患者的生存,总体不良事件耐受较好,对患者的生活质量无明显影响。因此,对于一些肿瘤控制良好、全身情况好、化疗耐受性好的患者可选择性延长化疗周期。
(安 欣 史艳侠)
参考文献
[1] PARK YH,JUNG KH,IM SA,et al.Phase Ⅲ multicenter randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy:KCSG-BR07-02.J Clin Oncol,2013,31(14):1732-1739.
[2] PARK YH,JUNG KH,IM SA,et al.Quality of life(QoL)in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine(PG)chemotherapy:results from phase Ⅲmulticenter,randomized trial of maintenance chemotherapy versus observation(KCSG-BR07-02).Breast Cancer Res Treat,2015,152(1):77-85.